Table 3: Previous case reports of patients with mCRC and severe liver dysfunction treated with FOLFOX (reprinted with permission from JNCCN, Journal of the National Comprehensive Cancer Network [7]).

Age (y), sexmFOLFOX6 (each drug dose: mg/m2)Total bilirubin (mg/dL)CEA (ng/mL)ResponseFOLFOX cycles until disease progression
1st cycle progressiona2nd cycleaBaselineAfter 2 cyclesBaselineAfter 2 cycles

Case  1: 63, M [6]Bolus 5-FU: 300, IV 5-FU: 1800, LV: 200, Ox: 60Bolus 5-FU: 400, IV 5-FU: 240, LV: 400, Ox: 853.51.2188.04.8PR14

Case  2: 59, F [6]Bolus 5-FU: 0, IV 5-FU: 2000, LV: 400, Ox: 65Bolus 5-FU: 0, IV 5-FU: 2400, LV: 400, Ox: 855.92.11.3895.0SD8

Case  3: 37, F [6]Bolus 5-FU: 0, IV 5-FU: 200, LV: 400, Ox: 85Bolus 5-FU: 400, IV 5-FU: 2400, LV: 400, Ox: 854.22.13685.0937.0PR≥10

Case  4: 67, M [7]Bolus 5-FU: 200, IV 5-FU: 1200, LV: 200, Ox: 75Bolus 5-FU: 200, IV 5-FU: 1200, LV: 200, Ox: 759.42.412.24.0PR21

Case  5: 58, F [8]Bolus 5-FU: 0, IV 5-FU: 2400, L-LV: 200, Ox: 85Bolus 5-FU: 400, IV 5-FU: 2400, L-LV: 200, Ox: 853.92.2103.196.0SD6

CEA: carcinoembryonic antigen; F: female; FOLFOX: 5-FU, leucovorin, and oxaliplatin; IV: infusional; L-LV: levoleucovorin; LV: leucovorin; M: male; Ox: oxaliplatin; PR: partial response; SD: stable disease.
aBolus 5-FU, infusional 5-FU, LV, and oxaliplatin.